Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kalaris Therapeutics (KLRS) Net Income (2019 - 2020)

Kalaris Therapeutics (KLRS) has 2 years of Net Income data on record, last reported at -$24.8 million in Q4 2020.

  • For Q4 2020, Net Income fell 180.78% year-over-year to -$24.8 million; the TTM value through Dec 2020 reached -$70.0 million, changed N/A, while the annual FY2024 figure was -$58.8 million, 131.64% down from the prior year.
  • Net Income reached -$24.8 million in Q4 2020 per KLRS's latest filing, down from -$23.8 million in the prior quarter.
  • Across five years, Net Income topped out at -$7.7 million in Q3 2019 and bottomed at -$24.8 million in Q4 2020.